Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.
The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief
Latest funding size
Time since last funding
|5AM Ventures, venBio Partners, Vivo Capital, Alliance of Angels|